ALIPAY
15.5.2020 04:25:13 CEST | Business Wire | Press release
Alipay, the world’s leading open digital lifestyle platform operated by Ant Financial Services Group (“Ant Group”), organized the inaugural Alipay Risk & Security Tech Launch 2020, showcasing its latest technologies that help businesses adapt to digital transformation in a secure way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200514005941/en/
At the event, Alipay unveiled the enhanced version of the AI-powered risk engine AlphaRisk, the core of its world-leading risk and security technologies. Backed by AlphaRisk, Alipay’s fraud loss rate has been kept under 0.64 in 10 million. This means that for every $10 million worth of payments, fraud induced loss is less than $0.64, which is significantly lower than industry average.
“The pandemic has accelerated digital transformation across the globe. Businesses and services which can adapt quicker to this growing trend will be in a stronger position to serve customers. Meanwhile, rapid digitization also comes with new challenges in risk and security,” said Dr. Zhao Wenbiao, Vice President of Ant Group and Chief Scientist of Alipay Security Lab in his keynote speech. “Security, more now than ever, has to be the core infrastructure for digital businesses to ensure operational safety and reliability, while continuously improving user experience and performance.”
With four main features, namely AI Detection, Evolution, Perception and Auto Pilot, AlphaRisk offers best-in-class real-time risk detection and management capabilities. It automatically analyzes fraud attempts and patterns to adjust risk profiles, and takes countermeasures on the fly. It is also able to detect new fraud patterns and automatically intervene.
The enhanced AlphaRisk is able to respond to new risks detected within one second and complete automatic risk profile adjustments within one day through self-learning and model auto-refit. Its Auto Pilot feature integrates more than 200 algorithms, which enables the system to automatically apply the best risk management strategy while ensuring seamless user experience.
“Alipay’s utmost priority is to build a safe and trusted digital lifestyle platform for the 1.2 billion users we serve with our global partners worldwide,” said Dr. Zhao. “Through opening up our technologies and close collaboration, we plan to further our support for partners and merchants by empowering their risk and security infrastructure and enhancing their anti-fraud capabilities. We look forward to working with our partners together to promote the sustainable development of digital economy.”
In addition to safeguarding user accounts, in 2019 alone, Alipay helped over 10,000 Independent Software Vendors (ISVs) and merchants deploy AlphaRisk. It has protected over RMB30 billion in funds from promotion abuse, a key challenge on the rise for digital businesses. In addition to the financial costs, promotion abuse can also damage brand reputation and the ability to acquire and retain real customers.
Alipay’s risk engine and technology have also been adopted by leading mobile financial services providers in the region, including GCash, the leading mobile wallet in the Philippines. GCash currently has over 20 million registered users who access the mobile wallet for its payment, remittance and financial services, and over 75,000 QR merchant partners.
Speaking at the event, Ms Peach Lucienne Orbe, Head of Risk Decision Center at GCash shared: “At the beginning of our growth journey, we were facing challenges in adoption due to consumers’ lack of trust and security concerns. To overcome it, we have to tackle fraud and promotion abuses. The risk engine allows for real-time protection of transactions and risk intervention through API. Its authentication platform also supports dynamic verification for efficient fraud prevention without hampering user experience. As a result, we have significantly decreased promotion abuse to less than 1%, and improved our security capability. With these risk capabilities and confidence we have gained through such technologies, we were able to launch GCash Customer Protect last September, a program that ensures money-back guarantee for unauthorized transactions.”
In China, thanks to AlphaRisk helping to keep the fraud loss rate low, since 2005, Alipay has been protecting its users with a 100% money back protection scheme in the unlikely event of unauthorized account use.
Alipay Risk & Security Tech Launch 2020 event video is available here https://www.youtube.com/watch?v=sdAoJcuSqjQ , with English subtitles.
About Alipay
Alipay is the world's leading open digital lifestyle platform operated by Ant Group. In 2004, Alipay launched as an escrow service to address the issue of trust between online buyers and sellers in the early days of e-commerce in China. Continuously innovating to bring mobile payment to the world, Alipay serves more than 1.2 billion users worldwide together with its global e-wallet partners as of June 30, 2019.
Alipay has evolved from a payment tool to become a one-stop digital lifestyle platform. Through an open platform strategy, it introduces service providers from sectors such as local living, public services, and financial services, to bring consumers a more comprehensive experience. Along the way, it helps merchants digitalize their operations, promoting digital transformation in the service industry.
Alipay actively shares its financial technology experience with overseas partners, in order to bring inclusive financial services to the world. Working with more than 250 overseas financial institutions, Alipay created online payment channels for buyers and sellers in more than 200 countries and regions. When Chinese people travel abroad, they can pay directly using their mobile phones, and receive dedicated local merchant services through Alipay. These services have been introduced in 56 countries and regions. Tax reimbursement via Alipay is supported in 35 countries and regions, and Alipay supports 27 different currencies. In addition, foreign tourists and foreigners living in China can also use Alipay for mobile payments in the country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
